Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Hematology & Oncology Division, Penn State College of Medicine, Hershey, PA, United States.
Front Immunol. 2023 May 26;14:1197112. doi: 10.3389/fimmu.2023.1197112. eCollection 2023.
Loss of , found in several types of lymphoma, induces excessive CXCL13 secretion through RNA dysregulation contributing to body weight loss and early death in lymphoma model mice. Follicular lymphoma (FL) is associated with overexpressed BCL-2 and other genetic aberrations, including 6q-. We identified a novel gene on 6q25, " ()," from a transformed FL. TFL regulates several cytokines mRNA degradation, which has been suggested to underlie resolving inflammation. Fluorescence hybridization revealed a deletion of occurred in 13.6% of various B-cell lymphoma samples. We developed VavP- transgenic, TFL deficit mice (-Tg/ ) to seek how TFL affects disease progression in this lymphoma model. While -Tg mice developed lymphadenopathy and died around 50 weeks, -Tg/ mice lost body weight around 30 weeks and died about 20 weeks earlier than -Tg mice. Furthermore, we found a unique B220IgM cell population in the bone marrow of -Tg mice. cDNA array in this population revealed that Cxcl13 mRNA in -Tg/ mice expressed significantly higher than -Tg mice. In addition, bone marrow extracellular fluid and serum showed an extremely high Cxcl13 concentration in -Tg/ mice. Among bone marrow cells, the B220IgM fraction was the main producer of Cxcl13 in culture. A reporter assay demonstrated TFL regulates CXCL-13 induction of 3'UTR mRNA degradation in B lineage cells. These data suggest Tfl regulates Cxcl13 in B220IgM cells in the bone marrow, and a very high concentration of serum Cxcl13 arising from these cells may contribute to early death in lymphoma-bearing mice. Since several reports have suggested the association of CXCL13 expression with lymphoma, these findings provide new insights into cytokine regulation TFL in lymphoma.
在几种类型的淋巴瘤中发现的缺失会导致 RNA 失调,从而过度分泌 CXCL13,导致淋巴瘤模型小鼠体重减轻和早逝。滤泡性淋巴瘤 (FL) 与 BCL-2 过表达和其他遗传异常有关,包括 6q-。我们从转化的 FL 中鉴定出一个位于 6q25 的新基因,“()”。TFL 调节几种细胞因子的 mRNA 降解,这被认为是炎症消退的基础。荧光原位杂交显示,在各种 B 细胞淋巴瘤样本中,发生了 的缺失。我们开发了 VavP-转基因、TFL 缺陷小鼠 (-Tg/),以研究 TFL 如何影响这种淋巴瘤模型中的疾病进展。虽然 -Tg 小鼠出现了淋巴结病并在 50 周左右死亡,但 -Tg/ 小鼠在 30 周左右体重减轻,并比 -Tg 小鼠早约 20 周死亡。此外,我们在 -Tg 小鼠的骨髓中发现了一种独特的 B220IgM 细胞群。该群体的 cDNA 阵列显示,-Tg/ 小鼠的 Cxcl13 mRNA 表达明显高于 -Tg 小鼠。此外,骨髓细胞外液和血清中 -Tg/ 小鼠的 Cxcl13 浓度极高。在骨髓细胞中,B220IgM 亚群是培养中 Cxcl13 的主要产生者。报告基因分析表明,TFL 调节 B 谱系细胞中 CXCL-13 诱导的 3'UTR mRNA 降解。这些数据表明,Tfl 在骨髓中的 B220IgM 细胞中调节 Cxcl13,而这些细胞产生的高浓度血清 Cxcl13 可能导致淋巴瘤小鼠的早期死亡。由于有几项报告表明 CXCL13 表达与淋巴瘤有关,这些发现为细胞因子调节 TFL 在淋巴瘤中的作用提供了新的见解。